CardioDx Receives $58,000,000 Series F Round

  • Feed Type
  • Date
    8/27/2012
  • Company Name
    CardioDx
  • Mailing Address
    2500 Faber Place Palo Alto, CA 94303
  • Company Description
    Founded in 2004, CardioDx is a cardiovascular genomic diagnostics company located in Palo Alto, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
  • Website
    http://www.cardiodx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $58,000,000
  • Transaction Round
    Series F
  • Proceeds Purposes
    Proceeds from the financing will be used to support the commercial expansion of Corus CAD, the only clinically validated gene expression test for obstructive coronary artery disease, and to develop additional genomic diagnostics in the field of cardiovascular disease.
  • M&A Terms
  • Venture Investor
    Temasek Holdings
  • Venture Investor
    Longitude Capital Management
  • Venture Investor
    Artiman Ventures
  • Venture Investor
    Kleiner Perkins Caufield & Byers
  • Venture Investor
    JPMorgan Partners
  • Venture Investor
    Mohr Davidow Ventures
  • Venture Investor
    TPG Biotech
  • Venture Investor
    Intel Capital
  • Venture Investor
    Acadia Woods Ventures
  • Venture Investor
    Bright Capital
  • Venture Investor
    Pappas Ventures
  • Venture Investor
    DAG Ventures
  • Venture Investor
    Asset Management Company
  • Venture Investor
    GE Healthymagination Fund

By posting a comment, you agree to our terms and conditions.